Zeid Barakat, MBA, CEO, has more than 10 years of venture leadership experience across the bio-pharmaceutical, medical device, private equity and CRD space. He was co-founder of Aura Biosciences, a $100M biotech company. He was also co-founder and COO of Flyberry Capital, a $20M quant hedge fund. Zeid received his MBA from the Massachusetts Institute of Technology Sloan School of Management, a MA in Biotechnology from Harvard, and a BA in biochemistry from Bowdoin College.
Roya Khosravi-Far, PhD, PLD, CSO, is an established scientist with over 20 years of expertise advancing early discovery and translational research in cancer biology, cancer therapy and biomarker discovery. She was the driving force behind the core academic research while an Associate Professor of Pathology at Harvard Medical School and Beth Israel Deaconess Medical School, and now leads the PDAC science team at BiomaRx. She received her PhD at University of North Carolina at Chapel Hill, carried out a postdoctoral fellowship and Massachusetts Institute of Technology and obtained the certificate for Program in Leadership Development at Harvard Business School.